Physician profile
Sherryl J Rosen
NPI 1164441622
$16,128.40
in general payments reported to CMS, 2019-2025
24 companies · $2,980 in 2025
The $2,980 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,440 · 2022: $3,541 · 2023: $2,167 · 2024: $1,001 · 2025: $2,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,045 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,044.81 |
| Education | $102.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $3,607.08 | 2021-2025 | Qelbree |
| Abbvie INC. | $2,647.89 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,737.63 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,519.99 | 2021-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $1,133.63 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $899.55 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $776.78 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $684.67 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $641.45 | 2021-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $631.29 | 2021-2025 | |
| Alkermes, INC. | $437.96 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $307.61 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $222.19 | 2024-2025 | Cobenfy |
| Corium, LLC | $211.31 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $174.77 | 2023-2025 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $148.30 | 2021-2022 | |
| Indivior INC. | $98.42 | 2023-2025 | Sublocade, Perseris |
| Ironshore Pharmaceuticals INC. | $94.65 | 2023-2024 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $60.04 | 2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $30.51 | 2025 | Relexxii |
| Noven Therapeutics, LLC | $17.24 | 2021 | |
| Eisai INC. | $16.49 | 2021 | |
| Pear Therapeutics (US), INC. | $14.52 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.43 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherryl Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.